참고문헌
- Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123:182.e1-7. https://doi.org/10.1016/j.amjmed.2009.05.031
- Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, Versalovic J, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005;40:1785-91. https://doi.org/10.1086/430312
- Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46:S360-7. https://doi.org/10.1086/533592
- Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009;47:1640-4. https://doi.org/10.1128/JCM.02135-08
- Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007;45:S191-5. https://doi.org/10.1086/519470
- Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010;9:9-14. https://doi.org/10.1517/14740330903413514
- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 14th ed. Hudson, OH:Lexi-Comp, 2007: 1596-8.
- Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980;96:119-26. https://doi.org/10.1016/S0022-3476(80)80347-7
- Patanwala AE, Norris CJ, Nix DE, Kopp BJ, Erstad BL. Vancomycin dosing for pneumonia in critically ill trauma patients. J Trauma 2009;67:802-4. https://doi.org/10.1097/TA.0b013e31818e90d2
- Geraci JE. Vancomycin. Mayo Clin Proc 1977;52:631-4.
- Ambrose P, Winter ME. Vancomycin. Basic Clinical Pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2004:451-76.
- Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. https://doi.org/10.2146/ajhp080434
- Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009;49:1169-74. https://doi.org/10.1086/605636
- Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42:S5-12. https://doi.org/10.1086/491709
- Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009;28:398-402. https://doi.org/10.1097/INF.0b013e3181906e40
- Cunha BA. Vancomycin. Med Clin North Am 1995;79:817-31. https://doi.org/10.1016/S0025-7125(16)30041-4
- Cunha BA. Vancomycin revisited: A reappraisal of clinical use. Crit Care Clin 2008;24:393-420. https://doi.org/10.1016/j.ccc.2007.12.012
- American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. https://doi.org/10.1164/rccm.200405-644ST
- Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infection. Clin Pharmacokinet 2004;43:925-42. https://doi.org/10.2165/00003088-200443130-00005
- Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51. https://doi.org/10.1086/381093
- Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704. https://doi.org/10.1093/jac/dkl030
- Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcome for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-8. https://doi.org/10.1086/381202
- Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995;14:667-73. https://doi.org/10.1097/00006454-199508000-00004
- Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care 2000;15:1-4. https://doi.org/10.1053/jcrc.2000.0150001
- Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000;45:329-35. https://doi.org/10.1093/jac/45.3.329
- Nivoche Y, Contrepois A, Cremieux AC, Carbon C. Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. J Pharmacol Exp Ther 1982;222:237-40.
- Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit. Clin Pharmacokinet 2001;40:833-68. https://doi.org/10.2165/00003088-200140110-00004
- Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, et al. Predictor of mortality for methicillin resistant Staphylococcus aureus healthcare-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-55. https://doi.org/10.1378/chest.130.4.947
- Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44. https://doi.org/10.1001/archinte.166.19.2138
피인용 문헌
- The Effect of Age and Weight on Vancomycin Serum Trough Concentrations in Pediatric Patients vol.33, pp.12, 2010, https://doi.org/10.1002/phar.1331
- Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure vol.32, pp.4, 2010, https://doi.org/10.1097/inf.0b013e318286378e
- Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines vol.34, pp.1, 2010, https://doi.org/10.3343/alm.2014.34.1.1
- Evaluation of Vancomycin Dosing and Corresponding Drug Concentrations in Pediatric Patients vol.4, pp.6, 2010, https://doi.org/10.1542/hpeds.2014-0019
- Validation of a Pediatric Population Pharmacokinetic Model for Vancomycin vol.37, pp.3, 2010, https://doi.org/10.1097/ftd.0000000000000153
- Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia vol.37, pp.5, 2015, https://doi.org/10.1097/ftd.0000000000000190
- Trough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation vol.10, pp.11, 2015, https://doi.org/10.1371/journal.pone.0141016
- Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) ― Digest Version ― vol.81, pp.4, 2010, https://doi.org/10.1253/circj.cj-66-0138
- Vancomycin Therapeutic Regime Adjustment in Newborns and Infants with Bacterial Infection: Case Series vol.20, pp.4, 2010, https://doi.org/10.2174/1389201020666190319161511
- Association of Initial Trough Concentrations of Vancomycin with Outcomes in Pediatric Patients with Gram-Positive Bacterial Infection vol.43, pp.10, 2010, https://doi.org/10.1248/bpb.b19-01003